Board of Directors

Louis W. Sullivan, M.D. (Chairman of the Board)

The Honorable Louis W. Sullivan, M.D. has been our Chairman of the Board since 1998 and has been a director of our company since its formation.

Dr. Sullivan served as Secretary of Health and Human Services in the cabinet of President George H.W. Bush from 1989 to 1993. Since retiring from the Bush Administration, Dr. Sullivan has been associated with the Morehouse School of Medicine in Atlanta, Georgia. Currently, he serves as President Emeritus and he previously served as President and Dean of the School from 1981 to 1985 and as President from 1985 to 1989 and from 1993 to 2002.

Dr. Sullivan serves on the board of directors of Henry Schein Inc., United Therapeutics Corporation and Emergent BioSolutions Inc. Dr. Sullivan also serves as chairman of the National Health Museum in Atlanta, Georgia and as chairman of the Sullivan Alliance to Increase Diversity in the Health Profession.

Stephen M. Simes (Vice-Chairman, President and Chief Executive Officer)

Mr. Simes has served as our Vice Chairman, President and Chief Executive Officer, and a director of our company since 1998.

From 1994 to 1997, Mr. Simes was President, Chief Executive Officer and a Director of Unimed Pharmaceuticals, Inc., (currently a wholly owned subsidiary of Abbott Laboratories) a company with a product focus on infectious diseases, AIDS, endocrinology and oncology. From 1989 to 1993, Mr. Simes was Chairman, President and Chief Executive Officer of Gynex Pharmaceuticals, Inc., a company which concentrated on the AIDS, endocrinology, urology and growth disorders markets. In 1993, Gynex was acquired by Savient Pharmaceuticals Inc. (formerly Bio-Technology General Corp.), and from 1993 to 1994, Mr. Simes served as Senior Vice President and director of Savient Pharmaceuticals Inc. Mr. Simes's career in the pharmaceutical industry started in 1974 with G.D. Searle & Co. (now a part of Pfizer Inc.). Mr. Simes currently serves as our designee on the board of directors of Ceregene, Inc., a privately held biotechnology company focused on the treatment of major neurodegenerative disorders using the delivery of nervous system growth factors.

Fred Holubow (Director)

Mr. Holubow has been a director of our company since 1999. He has been Vice President of Pegasus Associates since he founded Pegasus in 1982. Pegasus Associates is currently an operating division of William Harris Investors, a registered investment advisory firm. He specializes in analyzing and investing in pharmaceutical and biotechnology companies.

Mr. Holubow has previously served on the board of directors of ThermoRetec Corporation, Savient Pharmaceuticals Inc. (formerly, Bio-Technology General Corp.), Gynex Pharmaceuticals, Inc. and Unimed Pharmaceuticals, Inc.

Ross J. Mangano (Director)

Ross Mangano was elected a director of our company in 1999. Mr. Mangano has been the President and a director of Oliver Estate, Inc., a management company specializing in investments in public and private companies, since 1971. He serves on the board of directors of several private companies and U.S. RealTel Inc.

Edward C. Rosenow, III, M.D. (Director)

Edward C. Rosenow, III, M.D. has been a director of our company since 1997. Dr. Rosenow is a Master Fellow of the American College of Physicians as well as Master Fellow the American College of Chest Physicians.

Dr. Rosenow was the Arthur M. and Gladys D. Gray Professor of Medicine at the Mayo Clinic from 1988 until his retirement in 1996. Beginning with his residency in 1960, Dr. Rosenow has worked at the Mayo Clinic in many professional capacities including as a Consultant in Internal Medicine (Thoracic Diseases) from 1966 to 1996, an Assistant Professor, Associate Professor and Professor of Medicine at the Mayo Clinic Medical School, President of the Mayo Clinic Staff in 1986, and Chair of the Division of Pulmonary and Critical Care Medicine from 1987 to 1994.

Dr. Rosenow has also served as a consultant to NASA, space station FREEDOM at the Johnson Space Center in Houston, Texas from 1989 to 1990 and as the President of the American College of Chest Physicians from 1989 to 1990. In 1998, he received the Mayo Distinguished Alumnus Award. Dr. Rosenow serves on the board of directors of Virex, Inc, a private company.

Stephen A. Sherwin, M.D. (Director)

Stephen A. Sherwin, M.D., has been a director of our company since 2010. Dr. Sherwin had previously been with Cell Genesys starting in March 1990 as chief executive officer and in March 1994, he was elected chairman of the board. From 1983 to 1990, Dr. Sherwin held various positions at Genentech, Inc., including vice president of Clinical Research. Prior to 1983, Dr. Sherwin was on the staff of the National Cancer Institute. Dr. Sherwin co-founded Abgenix (acquired by Amgen in 2006), a former subsidiary of Cell Genesys, and Ceregene, Inc., a former subsidiary of Cell Genesys for which he serves as chairman of the board. Dr. Sherwin is a member of the board of directors for Neurocrine Biosciences, Inc. and Rigel Pharmaceuticals, Inc. He is also a board member of the Biotechnology Industry Organization. Dr. Sherwin holds a B.A. in biology from Yale University and an M.D. from Harvard Medical School. He is board-certified in internal medicine and medical oncology.

John T. Potts, Jr., M.D. (Director)

Dr. Potts was elected as a director of our company in 2010. Dr. Potts had served as a director of Cell Genesys from 1997 until 2009. Starting in March 1995, he served as a director of Somatix Therapy Corporation. His career spans 40 years of distinguished service in science and medicine. He earned his M.D. in 1957 from the University of Pennsylvania, then trained at Massachusetts General Hospital and National Heart Institute. At the National Institutes of Health, he became head of the section on polypeptide hormones prior to becoming chief of endocrinology at Massachusetts General Hospital in 1968. Dr. Potts served as physician-in-chief at Massachusetts General Hospital and Jackson Professor of Clinical Medicine at Harvard Medical School from 1981 to 1996. In September 1996, he moved from the post of physician-in-chief to director of research at Massachusetts General Hospital and Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School.